A5056313972- Schizophrenia research and treatment
- Treatment of Major Depression
- Bipolar Disorder and Treatment
- Mental Health and Psychiatry
- Mental Health Research Topics
- Psychiatric care and mental health services
- Autism Spectrum Disorder Research
- Child Nutrition and Feeding Issues
- Health Systems, Economic Evaluations, Quality of Life
- Epilepsy research and treatment
- Obsessive-Compulsive Spectrum Disorders
- Diet and metabolism studies
- Pharmaceutical studies and practices
- Meta-analysis and systematic reviews
- Sleep and related disorders
- Transgenic Plants and Applications
- Gene expression and cancer classification
- Child and Adolescent Psychosocial and Emotional Development
- Cardiac electrophysiology and arrhythmias
- Electroconvulsive Therapy Studies
- Tryptophan and brain disorders
- Bioinformatics and Genomic Networks
- Microtubule and mitosis dynamics
- Healthcare Decision-Making and Restraints
- Childhood Cancer Survivors' Quality of Life
Technical University of Munich
2012-2023
Sozialstiftung Bamberg
2020-2023
Klinikum rechts der Isar
2012-2023
Klinik und Poliklinik für Psychiatrie und Psychotherapie
2012-2022
University of Bamberg
2022
Leipzig University
2021
München Klinik
2011-2019
University of Ioannina
2017
Institute of Social and Preventive Medicine
2017
University of Bern
2017
Psychological treatments are increasingly regarded as useful interventions for schizophrenia. However, a comprehensive evaluation of the available evidence is lacking and benefit psychological patients with current positive symptoms still debated. The present study aimed to evaluate efficacy, acceptability tolerability schizophrenia by applying network meta-analysis approach, that can integrate direct indirect comparisons. We searched EMBASE, MEDLINE, PsycINFO, PubMed, BIOSIS, Cochrane...
Most acute phase antipsychotic drug trials in schizophrenia last only a few weeks, but patients must usually take these drugs much longer. We examined the long-term efficacy of acutely ill using network meta-analysis. searched Cochrane Schizophrenia Group register up to March 6, 2022 for randomized, blinded at least 6-month duration on all second-generation and 18 first-generation antipsychotics. The primary outcome was change overall symptoms schizophrenia; secondary outcomes were all-cause...